

We are a leading European pharmaceutical company in the development and distribution of niche products and services for generic laboratories all over the world. Our mission is to reinforce and strengthen laboratory supply chains by providing a broad range of APIs from different origins.

Capital Farma produces Silver Sulfadiazine under the highest quality standards

Made in Europe in constant and standardized campaigns eCTD dossier. USP Specifications

## SILVER SULFADIAZINE

## **RELIABILITY PRODUCT OVERVIEW High security** ₩, **USP SPECIFICATIONS** demonstrated Standardized **Technical specifications &** Treatment of **Security Indicated** production Crystalline Recent Batches burns powder, white Indicated worldwide for **Side effects** Production in to creamy the treatment and uncommon **Europe** white. **Appearance** prevention of infections Local stock It darkens in second- and Does not withexposure **(** produce ocular thirddegree **QUALITY** to light irritation burns, as well as • EU GMP, USP varicose and decubitus Does not Micronization ulcers produce Service Identificaction Positive **BACTERIOSTATIC** and dermatitis ISO 9001 **BACTERICIDE** Action ISO 14000 Organ **%** GP • 15 annual audits No blood absorption malfunction 98.0 - 102.0%Assay rarely occurs from topical application **COMPETITIVENESS** No interaction with other medicines Production **Nitrate** ≤ 0.1% by campaigns **Very Rare:** Comprehensive • Toxic epidermic raw material necrolysis management Loss Steven Johnson ≤ 0.5% on drying **Syndrome SERVICE** Frequency NOT known: Photosensitise Silver • Free Samples 29.3 - 30.5% Dermatological Content • GDP Highly competitive problems Personalized pricing that impacts on the finished product attention Total Genuino et al., 2014 just 4%-8% (depending ≤ 0.5% J. S. Kim et al., 2013 Proximity offices impurities The Side Effects of Silver Sulfadiazine on the region)

We also provide a wide variety of alternative substances from different origines. For more information and to see our full product range, please get in contact with us at info@capitalfarma.com







Frederick W. Fuller, MD, 2009 (42 references)

